8 results on '"Eberhardt, Wilfried"'
Search Results
2. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
- Author
-
Wiesweg, Marcel, Preuß, Cedric, Roeper, Julia, Metzenmacher, Martin, Eberhardt, Wilfried, Stropiep, Ursula, Wedeken, Katrin, Reis, Henning, Herold, Thomas, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, Schildhaus, Hans-Ulrich, Schmid, Kurt W., Falk, Markus, Heukamp, Lukas, Tiemann, Markus, Griesinger, Frank, and Schuler, Martin
- Subjects
- *
LUNG cancer prognosis , *LUNG cancer , *SURVIVAL , *GENETIC mutation , *IMMUNE checkpoint inhibitors , *CANCER chemotherapy , *METASTASIS , *CANCER patients , *TREATMENT effectiveness , *TRANSFERASES , *DISEASE susceptibility , *DESCRIPTIVE statistics , *IMMUNOTHERAPY , *CANCER patient medical care , *LONGITUDINAL method , *THERAPEUTICS - Abstract
BRAF mutations have been subtyped in three functional classes with different oncogenic modes of action. The clinical impact of BRAF mutational subtypes in non–small-cell lung cancer (NSCLC) remains to be defined. So far, ambiguous results were reported from analyses of heterogeneous patient cohorts. We studied patients with metastatic or recurrent NSCLC who were sequentially enrolled in precision oncology programs at two large German lung cancer centres from 2009 to 2019. The study period allowed evaluating the specific impact of BRAF V600E-targeting. In a cohort of 72 patients, BRAF mutation subtyping revealed p.V600E mutations in 31 cases (43%), whereas 41 cases (57%) harboured 18 different BRAF mutational subtypes of functional classes II/III. Functionally relevant comutations were observed in 6.4% of class I, and 24.4% of class II/III BRAF mutations. Most patients were treated with chemotherapy. Targeted therapy was administered in 11 patients with a response rate of 72.7%. PD-1/PD-L1-immunotherapy was given in 14 patients with a response rate of 28.6%. Overall survival of patients with BRAF -mutated NSCLC was inferior (HR 1.38, p = 0.048) as compared to patients with BRAF wild-type cancers. Median time-to-treatment-failure with BRAF-targeting agents was shorter as compared to approved targeted therapy of other oncogenic drivers (HR 1.97, p = 0.05). Survival outcomes were not impacted by BRAF mutation subtype functional class. Patients with BRAF -mutated NSCLC have an inferior prognosis, which is not determined by BRAF mutation functional class. In contrast to NSCLC with other tractable driver mutations, BRAF -mutated NSCLC exhibit high susceptibility to immune checkpoint inhibitors. • PD-1/PD-L1 immunotherapy is effective in BRAF -mutant NSCLC. • Patients with BRAF -mutated NSCLC have inferior overall survival. • BRAF mutation functional class does not associate with clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
- Author
-
Schotten, Lea M., Darwiche, Kaid, Seweryn, Michal, Yildiz, Vedat, Kneuertz, Peter J., Eberhardt, Wilfried E.E., Eisenmann, Stephan, Welter, Stefan, Sisson, Brianna E., Pietrzak, Maciej, Wiesweg, Marcel, Ploenes, Till, Hager, Thomas, He, Kai, Freitag, Lutz, Aigner, Clemens, Taube, Christian, and Oezkan, Filiz
- Subjects
- *
BIOMARKERS , *IDENTIFICATION , *AGE distribution , *CELL receptors , *PATIENTS , *LUNG tumors , *RETROSPECTIVE studies , *EARLY detection of cancer , *DNA methylation , *CANCER patients , *DNA-binding proteins , *OBSTRUCTIVE lung diseases , *DESCRIPTIVE statistics , *PREDICTIVE validity , *SMOKING , *DECISION making in clinical medicine , *EVALUATION , *BLOOD - Abstract
In contrast to patients who present with advanced stage lung cancer and associated poor prognosis, patients with early-stage lung cancer may be candidates for curative treatments. The results of the NELSON lung cancer screening trial are expected to stimulate the development and implementation of a lung cancer screening strategy in most countries. Widespread use of chest computed tomography scans will also result in the detection of solitary pulmonary nodules. Because reliable biomarkers to distinguish between malignant and benign lesions are lacking, tissue-based histopathological diagnostics remain the gold standard. In this study, we aimed to establish a test to assess the predictive ability of DNA hypermethylation of SHOX2 and PTGER4 in plasma to discriminate between patients with 1.) lung cancer, 2.) benign lesions, and 3.) patients with chronic obstructive pulmonary disease (COPD). We retrospectively analysed SHOX2 and PTGER4 methylation in 121 prospectively collected plasma samples of patients with lung cancer (group 1A), benign lesions (group 1B), and COPD without nodules (group 2). PTGER4 DNA hypermethylation was more frequently observed in patients with lung cancer than in controls (p = 0.0004). Results remained significant after correction for tumour volume, smoking status, age, and eligibility for the NELSON trial. Detection of methylated PTGER4 in plasma DNA may serve as a biomarker to support clinical decision-making in patients with pulmonary lesions at lung cancer screening in high-risk populations. Further exploration in prospective studies is warranted. • mPTGER4 and mSHOX2 were assessed to improve lung cancer diagnostics. • Lung cancer was compared with benign pulmonary nodules and COPD. • Hypermethylation of PTGER4 helps to distinguish patients with lung cancer from controls. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Neoadjuvant and adjuvant end-points in health technology assessment in oncology.
- Author
-
Harbeck, Nadia, Schneeweiss, Andreas, Thuss-Patience, Peter, Miller, Kurt, Garbe, Claus, Griesinger, Frank, Eberhardt, Wilfried E.E., Klussmann, Jens P., Wollenberg, Barbara, Grimm, Marc-Oliver, Zander, Thomas, and Lüftner, Diana
- Subjects
- *
MEDICAL technology evaluation , *SURVIVAL , *DRUG efficacy , *HEALTH services accessibility , *LIFE expectancy , *CANCER relapse , *ADJUVANT treatment of cancer , *CHEMORADIOTHERAPY , *PATIENTS' attitudes , *RISK assessment , *COMBINED modality therapy , *CANCER patient medical care , *DISEASE risk factors - Abstract
Health technology assessment (HTA) of clinical and economic value of a new intervention is an integral step in providing the access of patients to innovative cancer care and treatment. Overall survival (OS) is the preferred criterion for demonstrating the therapeutic efficacy in HTA given its direct clinical and patient relevance. However, with often long life expectancy of patients with early cancer, analysis of OS becomes less practical. Partially due to this reason, pathological complete response (pCR) and time-to-event end-points like disease-free survival are frequently incorporated into the pivotal clinical trials in the neoadjuvant and adjuvant settings. However, there exists a discrepancy between different national HTA bodies regarding the acknowledgement of patient relevance of these end-points. In this article, we analysed the perspectives of patients on different aspects of end-points used in clinical trials in early cancer. Gathered evidence strongly suggests that complete tumour eradication and reduced risk of recurrence provide important psychological benefits thus signifying that pCR and time-to-event end-points are directly relevant to patients. Additionally, we reviewed opinions on patient relevance of neoadjuvant and adjuvant therapy end-points adopted by HTA bodies during the recent evaluations. We found that improvements in end-points used in the adjuvant setting were commonly considered as valuable to patients. In contrast, opinions on patient relevance of neoadjuvant therapy end-points varied between the national HTA bodies. Universal acknowledgement of patient relevance of therapeutic end-points for early cancer by HTA bodies is necessary to balance the inequality in uptake of innovative therapies into national healthcare systems. • Tumour eradication and reduced risk of recurrence are important to patients. • Time-to-event end-points are commonly accepted in health technology assessment (HTA). • Pathological complete response is often not considered as patient-relevant in HTA. • Adoption of (neo)adjuvant end-points in HTA improves access to innovative therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
- Author
-
Wiesweg, Marcel, Mairinger, Fabian, Reis, Henning, Goetz, Moritz, Kollmeier, Jens, Misch, Daniel, Stephan-Falkenau, Susann, Mairinger, Thomas, Walter, Robert F.H., Hager, Thomas, Metzenmacher, Martin, Eberhardt, Wilfried E.E., Zaun, Gregor, Köster, Johannes, Stuschke, Martin, Aigner, Clemens, Darwiche, Kaid, Schmid, Kurt W., Rahmann, Sven, and Schuler, Martin
- Subjects
- *
BIOPSY , *CANCER patients , *IMMUNOHISTOCHEMISTRY , *IMMUNOTHERAPY , *LUNG cancer , *MACHINE learning , *MEMBRANE proteins , *MULTIVARIATE analysis , *RNA , *TUMOR markers , *BIOINFORMATICS , *PREDICTION models , *TREATMENT effectiveness , *GENE expression profiling , *DESCRIPTIVE statistics , *IMMUNE checkpoint inhibitors , *EVALUATION , *THERAPEUTICS - Abstract
Current predictive biomarkers for PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1)-directed immunotherapy in non-small cell lung cancer (NSCLC) mostly focus on features of tumour cells. However, the tumour microenvironment and immune context are expected to play major roles in governing therapy response. Against this background, we set out to apply context-sensitive feature selection and machine learning approaches on expression profiles of immune-related genes in diagnostic biopsies of patients with stage IV NSCLC. RNA expression levels were determined using the NanoString nCounter platform in formalin-fixed paraffin-embedded tumour biopsies obtained during the diagnostic workup of stage IV NSCLC from two thoracic oncology centres. A 770-gene panel covering immune-related genes and control genes was used. We applied supervised machine learning methods for feature selection and generation of predictive models. Feature selection and model creation were based on a training cohort of 55 patients with recurrent NSCLC treated with PD-1/PD-L1 antibody therapy. Resulting models identified patients with superior outcomes to immunotherapy, as validated in two subsequently recruited, separate patient cohorts (n = 67, hazard ratio = 0.46, p = 0.035). The predictive information obtained from these models was orthogonal to PD-L1 expression as per immunohistochemistry: Selecting by PD-L1 positivity at immunohistochemistry plus model prediction identified patients with highly favourable outcomes. Independence of PD-L1 positivity and model predictions were confirmed in multivariate analysis. Visualisation of the models revealed the predictive superiority of the entire 7-gene context over any single gene. Using context-sensitive assays and bioinformatics capturing the tumour immune context allows precise prediction of response to PD-1/PD-L1-directed immunotherapy in NSCLC. • Establishment of a novel predictor of immunotherapy response in lung cancer. • Machine-learning approach increases precision by integrating tumor immune context. • Gene expression context is more powerful than single markers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
- Author
-
Guberina, Nika, Pöttgen, Christoph, Schuler, Martin, Guberina, Maja, Stamatis, Georgios, Plönes, Till, Krebs, Bettina, Metzenmacher, Martin, Theegarten, Dirk, Gauler, Thomas, Jöckel, Karl-Heinz, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, and Eberhardt, Wilfried E.
- Subjects
- *
LUNG cancer prognosis , *ADJUVANT treatment of cancer , *CANCER chemotherapy , *CANCER patients , *CONFIDENCE intervals , *LUNG cancer , *MEDICAL records , *MULTIVARIATE analysis , *TUMOR classification , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *ACQUISITION of data methodology , *CHEMORADIOTHERAPY - Abstract
The optimal treatment for patients with locally advanced non-small-cell lung-cancer (NSCLC) cT4 cN0/1 cM0 is still under debate. The purpose of this study was to examine the long-term survival of cT4 cN0/1 cM0 NSCLC patients undergoing induction chemotherapy and concurrent radiochemotherapy before surgery. All consecutive patients with confirmed NSCLC (cT4 cN0/1 cM0) treated with neoadjuvant chemotherapy, concurrent radiochemotherapy (RT/CTx) (45–46 Gy) and surgical resection between 2000 and 2015 were included. According to the UICC guidelines (8th edition), T4 stage was reanalysed by an expert radiologist. The mediastinal staging was performed by systematic EBUS-TBNA or mediastinoscopy. The primary end-point was overall-survival (OS). The power to detect an increase of early tumour-associated mortality (hazard ratio > 3.5) within the first 5 years after treatment in comparison to late deaths beyond 96 months was >80%. Overall, 67 patients were treated with concurrent RT/CTx. T4 criteria were fulfilled by all patients, and multiple T4 criteria by 53 patients. Seventy percent of patients had an initial PET/CT staging. The median follow-up period was 134 months. OS rates at 2, 5, 10 and 15 years were 83.6 ± 4.5%, 65.4 ± 5.9%, 53.3 ± 6.3% and 36.6 ± 6.8%, respectively. A total of 44.8% of patients achieved a pathologic complete response. In multivariable analysis, ypT category was the most predictive factor. OS at 5 years for ypT0 (n = 31) was 80.5%, and ypT1 (n = 11) was 62.5%. Main sites of failure were brain and pulmonary metastases in seven and three patients, respectively. The intercurrent annual death rate was estimated from the survival curve beyond 96 months and was found to be 4.75% (95% CI 2.40–9.27%). No significant increased mortality was observed during the first 5 years (annual death rate: 8.31% [95% CI 5.60–12.24%], hazard-ratio = 1.72 [95% CI 0.81–3.65]). The effectiveness of this trimodality schedule is high in patients with cT4 cN0/1 cM0 NSCLC with excellent local control rates. Considering the annual death rate beyond 8 years of survival as an intercurrent death rate due to comorbidity, this treatment schedule reduces annual mortality to background even in the first 5 years after therapy. • Neoadjuvant radiochemotherapy in cT4 N0/1 NSCLC associated with ypT0-downstaging of 63%. • Patients have overall survival above 80% at 5-years after resection setting a benchmark. • Trimodal treatment reduces annual mortality to background even in 5 years post-therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center.
- Author
-
Wiesweg, Marcel, Ting, Saskia, Reis, Henning, Worm, Karl, Kasper, Stefan, Tewes, Mitra, Welt, Anja, Richly, Heike, Meiler, Johannes, Bauer, Sebastian, Hense, Jörg, Gauler, Thomas C., Köhler, Jens, Eberhardt, Wilfried E., Darwiche, Kaid, Freitag, Lutz, Stamatis, Georgios, Breitenbücher, Frank, Wohlschlaeger, Jeremias, and Theegarten, Dirk
- Subjects
- *
BIOMARKERS , *COLON tumors , *IMMUNOHISTOCHEMISTRY , *LUNG cancer , *GENETIC mutation , *DESCRIPTIVE statistics ,RECTUM tumors - Abstract
Abstract: Purpose: Multiple investigational drugs are currently explored in cancer patient populations defined by specific biomarkers. This demands a new process of patient selection for clinical trials. Patients and methods: Starting January 1, 2012, preemptive biomarker profiling was offered at the West German Cancer Center to all patients with advanced non-small-cell lung (NSCLC) or colorectal cancer (CRC), who met generic study inclusion criteria. Tumour specimens were subjected to prespecified profiling algorithms to detect ‘actionable biomarkers’ by amplicon sequencing, in situ hybridisation and immunohistochemistry. The clinical course was closely monitored to offer trial participation whenever applicable. Results: Within 12 months, 267 patients (188 NSCLC, 79 CRC) were profiled. Estimated additional cost for biomarker profiling was 219615.51 EUR excluding histopathology workup and administration. The most prevalent biomarkers in pulmonary adenocarcinoma were KRAS mutations (29%), loss of PTEN expression (18%), EGFR mutations (9%), HER2 amplification (5%) and BRAF mutations (3%), while the prevalence of ALK translocations and PIK3CA mutations was extremely low. In pulmonary squamous cell carcinoma FGFR1 amplifications were found in 15%, PTEN expression was lost in 20% and DDR2 was mutated in a single case. KRAS mutations (41%) predominated in CRC, followed by loss of PTEN expression (16%), PIK3CA (5%) and BRAF (5%) mutations. So far 13 patients (5%) have entered biomarker-stratified clinical trials. Therapeutic decisions for approved drugs were guided in another 45 patients (17%). Conclusion: Preemptive biomarker profiling can be implemented into the diagnostic algorithm of a large Comprehensive Cancer Center. Substantial investments in diagnostics and administration are required. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.
- Author
-
Gauler, Thomas Christoph, Christoph, Daniel Christian, Fischer, Juergen, Frickhofen, Norbert, Huber, Rudolf, Gonschorek, Christine, Roth, Katrin, Giurescu, Marius, and Eberhardt, Wilfried Ernst Erich
- Subjects
- *
ANTINEOPLASTIC agents , *COMBINATION drug therapy , *CISPLATIN , *LUNG cancer , *METASTASIS , *DESCRIPTIVE statistics - Abstract
Abstract: Background: Sagopilone (ZK219477) is a new and fully synthetic epothilone with activity against multi-drug resistant tumour cell lines. It has demonstrated clinical activity in several solid tumours like ovarian cancer and melanoma. Data about clinical efficacy of sagopilone in small-cell lung cancer are lacking. Here we report the first phase-I trial of sagopilone in combination with cisplatin in previously untreated metastatic small-cell lung cancer patients. Methods: Chemonaive patients with metastatic small-cell lung cancer (SCLC) received sagopilone in four different dosing schedules ranging from 12 to 22mg/m2 (on day 1 as 3-h infusion) followed by a fixed dose of cisplatin of 75mg/m2 as 1-h infusion on day 1. Chemotherapy was administered every 3weeks to a maximum of six cycles. The primary objective was determination of dose-limiting toxicities (DLTs) and the maximum-tolerated dose (MTD) in this setting. Secondary objectives were assessment of objective response rates (ORR) as well as investigation of sagopilone pharmacokinetics. Results: Twenty-six patients received a total of 107 treatment cycles of the platinum–sagopilone doublet. The recommended phase-II dose (RD) and schedule was found to be 19mg/m2 sagopilone followed by 75mg/m2 cisplatin. Peripheral neuropathy turned out as dose-limiting toxicity when the combination was administered over a median of four cycles. Objective responses were observed in six out of seven SCLC patients (85.7%) treated with the RD. Conclusions: Sagopilone and cisplatin can be safely combined in the first-line treatment of metastasised SCLC. This combination demonstrated preliminary efficacy and should be further evaluated within phase-II trials. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.